Infinity Bio Emphasizes Immune-Ageing Research and Antibody Reactome Profiling Strategy

According to a recent LinkedIn post from Infinity Bio Inc, the company is spotlighting a Nature study that constructs a “Human Immune Health Atlas” using multi-omic profiling of more than 300 adults aged 25–90. The post underscores evidence that immune ageing follows dynamic, non-linear molecular transitions that begin earlier than traditional “advanced age” cutoffs.

The LinkedIn post highlights key findings such as early transcriptional reprogramming in naïve T cells, a progressive TH2-like bias in ageing memory T cells, and links between these changes and impaired vaccine responses. The study also introduces an RNA Age Metric, which appears to correlate with established ageing measures and could help differentiate biological from chronological immune age.

The post suggests that these insights may support more targeted vaccine and therapy design tailored to an individual’s biological age, potentially expanding future demand for high-resolution immune monitoring tools. As part of its “Cohort of the Week” series, Infinity Bio positions large-scale biomarker measurements as a foundation for such discoveries, aligning its brand with cutting-edge multi-omic cohort research.

According to the post, Infinity Bio sees an opportunity for its Antibody Reactome Profiling to add value in similar cohorts by mapping cumulative exposure to self, viral, and environmental antigens. The company indicates this approach could assess whether early “pre-ageing” transcriptional shifts reduce antibody repertoire breadth and identify individuals at higher risk of autoimmune pathology based on immune-age metrics.

For investors, the emphasis on Reactome-based antibody profiling within longitudinal cohort studies points to a strategy centered on high-content immune analytics and precision immunology. If adopted broadly by academic, clinical, or biopharma partners, such capabilities could support recurring revenue from cohort analytics, differentiation in the immune-ageing niche, and potential participation in the development of age-tailored vaccines and therapeutics.